Novartis signed a research and licensing agreement with Unnatural Products to apply UNP’s AI‑driven macrocyclic peptide platform to cardiovascular targets, with the collaboration worth up to $1.8 billion in milestones. Novartis will lead IND‑enabling work, clinical development and commercialization; UNP will receive upfront payments and tiered royalties. The deal pairs UNP’s computational macrocycle design and parallel synthesis capabilities with Novartis’ global development infrastructure. Novartis also made a separate commitment tied to UNP technology — signaling pharmaceutical interest in macrocycles as a modality to engage previously intractable targets.